Copenhagen, Denmark, Friday 24 April: HIV positive and HIV negative patients have comparable survival rates following liver transplant, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark.
The study results showed no difference in survival rates at 1 and 5 years between HIV negative and HIV positive patients (86.5% and 74% versus 87.1% and 78%, p=0.843), suggesting a good prognosis for HIV positive patients following liver transplant. However, the study confirmed that co-infection with hepatitis C virus (HCV) is a significant predictor of poorer survival rates in patients with HIV. Survival rates at 1 and 5 years were 73% and 53% in HIV positive patients with hepatitis C versus 87% and 69% (p=0.047) in HIV negative patients with hepatitis C.
Doctor Kosh Agarwal, of the Institute of Liver Studies, Kings College Hospital, London, who led the study said: "Data on long term outcomes from liver transplantation in HIV patients is limited. These study results are valuable confirmation that selected HIV positive patients are as suitable candidates for liver transplant as HIV negative patients and should have similar access to treatment. However, those patients with co-infection with hepatitis C did less well, emphasising the need for appropriate antiviral therapy early in the course of their HCV related liver disease. In the context of co-infection, these data emphasise the need to develop newer and more innovative treatment strategies. These should include exposure to new small molecule therapies for HCV that are currently being explored in mono-infection."
The researchers conducted a prospective analysis of the UK Transplant Database to determine the long-term outcomes in HIV patients undergoing liver transplant in the UK. They examined 6,315 adult patients (>18 years) undergoing their first liver transplant between March 1994 and April 2008. The patient groups compared in this analysis included:
The three patient groups were comparable according to the Model End Stage Liver Disease (MELD) scores, which is a numerical scale to score disease severity and improve organ allocation in transplantation. HIV positive patients were younger compared to HIV negative patients (mean 42.2 years versus 51.2, p=0.001) and HIV positive patients co-infected with hepatitis C were younger (mean 39.9 years versus 51.8; p=0.0001) than HIV negative patients with hepatitis C.
For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EASL congress press office on:
Onsite tel: +44 (0) 7876 190 439
Mette Thorn Sørensen:
Onsite tel: +45 41 38 43 00
EASL (The European Association for the Study of the Liver) is the leading European scientific society involved in promoting research and education in Hepatology. EASL is a large society with a membership of over 1500 from 15 leading countries. Since its formation in 1966, members of the society have given rise to a high number of studies in clinical Hepatology and on the basic aspects of liver diseases, for the benefit of patients all over the world.
The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver (EASL), is taking place in Copenhagen, Denmark, 22 April 2009. The official website is: http://www.easl.eu. Over 7,000 clinicians and scientists are expected to attend EASL 2009. Over the course of the Meeting, 144 oral presentations and 199 posters drawn from over 2179 abstract submissions will be featured.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.